PCSK9 Inhibitors

How it works

Benefits

Comparisons

Evidence quality

Highlighted claims

• PCSK9 monoclonal antibodies reduce LDL-C by about 60% and have reduced cardiovascular events after ACS. — PCSK9 inhibitoRs for Early Passivation of coRonary athEroSclerotic plaqueS in acute coronary syndromes (REPRESS): study protocol for a multicentre randomised controlled trial
• The short-term effect of early PCSK9 inhibition on non-culprit plaque morphology after ACS remains insufficiently established. — PCSK9 inhibitoRs for Early Passivation of coRonary athEroSclerotic plaqueS in acute coronary syndromes (REPRESS): study protocol for a multicentre randomised controlled trial
• Inclisiran lowers LDL-C by approximately 50% by targeting hepatic PCSK9 production. — PCSK9 inhibitoRs for Early Passivation of coRonary athEroSclerotic plaqueS in acute coronary syndromes (REPRESS): study protocol for a multicentre randomised controlled trial
• Prior early in-hospital PCSK9 inhibition studies found substantial LDL-C reduction and higher target-attainment rates within 2 to 8 weeks after discharge. — PCSK9 inhibitoRs for Early Passivation of coRonary athEroSclerotic plaqueS in acute coronary syndromes (REPRESS): study protocol for a multicentre randomised controlled trial
• REPRESS includes both evolocumab and inclisiran, but this is a limitation because they lack direct head-to-head randomised trial comparison. — PCSK9 inhibitoRs for Early Passivation of coRonary athEroSclerotic plaqueS in acute coronary syndromes (REPRESS): study protocol for a multicentre randomised controlled trial